Dietary supplementation with n-3 polyunsaturated fatty acids and vi- tamin E after myocardial infarction: results of the GISSI-Prevenzione trial: Gruppo Italiano per lo Studio della Sopravvivenza nell Infarto miocardico [published corrections appear in Lancet. 2001;357:642 and Lancet. 2007;369:106]. Lancet. 1999;354:447 455. 282. Scirica BM, Morrow DA, Cannon CP, Ray KK, Sabatine MS, Jarolim P, Shui A, McCabe CH, Braunwald E; PROVE IT-TIMI 22 Investigators. Intensive statin therapy and the risk of hospitaliza- tion for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study [published correction appears in J Am Coll Cardiol. 2013;62:1727]. J Am Coll Cardiol. 2006;47:2326 2331. doi: 10.1016/j.jacc.2006.03.034. 283. Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart. 2007;93:914 921. doi: 10.1136/hrt.2006.112508. 284. Strandberg TE, Holme I, Faergeman O, Kastelein JJ, Lindahl C, Larsen ML, Olsson AG, Pedersen TR, Tikkanen MJ; IDEAL Study Group. Comparative effect of atorvastatin (80 mg) versus simv- astatin (20 to 40 mg) in preventing hospitalizations for heart fail- ure in patients with previous myocardial infarction. Am J Cardiol. 2009;103:1381 1385. doi: 10.1016/j.amjcard.2009.01.377. 285. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001 1009. doi: 10.1056/NEJM199610033351401. 286. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011:CD004816. 287. Alberti KG, Zimmet PZ. 